Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins
Open Access
- 1 May 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (9) , 3815-3822
- https://doi.org/10.1158/0008-5472.can-04-2478
Abstract
Histone acetylation and deacetylation are crucial in the regulation of gene expression. Dynamic changes in gene expression may affect chromatin structure and, consequently, the interaction of chromatin with regulatory factors. In this study, the effects of the antiseizure drug valproic acid (VPA) on the expression of genes that regulate the structure of chromatin and the access of macromolecules to the DNA were investigated. Exposure of breast cancer cells to VPA resulted in rapid dose-dependent hyperacetylation of the histones H3 and H4. VPA further induced a depletion of several members of the structural maintenance of chromatin (SMC) proteins, SMC-associated proteins, DNA methyltransferase, and heterochromatin proteins. Down-regulation of these proteins was associated with chromatin decondensation. The observed alterations of chromatin structure correlated with enhanced sensitivity of DNA to nucleases and increased interaction of DNA with intercalating agents. VPA-induced chromatin decondensation led to a sequence-specific potentiation of DNA-damaging agents in cell culture and xenograft models. Modulation of heterochromatin maintenance proteins was not a direct, but a downstream, effect of histone acetylation. The effects on the chromatin structure were reversible upon drug withdrawal, but obligatory for the potentiation of DNA-damaging agents. In addition to their antitumor activity as single agents, the chromatin decondensation induced by histone deacetylase inhibitors may enhance the efficacy of cytotoxic agents that act by targeting DNA. The proposed mechanism of action suggests an effect of drug sequencing on the antitumor activity of these drugs.Keywords
This publication has 28 references indexed in Scilit:
- Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 2004
- Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular DifferentiationCancer Research, 2004
- Anti‐tumor mechanisms of valproate: A novel role for an old drugMedicinal Research Reviews, 2002
- Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome StabilityCell, 2001
- Dnmt3a and Dnmt3b Are Transcriptional Repressors That Exhibit Unique Localization Properties to HeterochromatinJournal of Biological Chemistry, 2001
- Recombinant Human DNA (Cytosine-5) MethyltransferaseJournal of Biological Chemistry, 1999
- Valproic acid for the treatment of pediatric malignant gliomaKlinische Padiatrie, 1999
- Sodium valproate inhibits in vivo growth of human neuroblastoma cellsAnti-Cancer Drugs, 1997
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI Journal of the National Cancer Institute, 1994
- Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurementsCytometry, 1990